Skip to main content
. 2022 Mar 25;40(21):2321–2332. doi: 10.1200/JCO.21.02198

TABLE 3.

OS and PFS by PD-L1 Subgroup in Participants Receiving Pembrolizumab-Chemotherapy Versus Cetuximab-Chemotherapy

graphic file with name jco-40-2321-g006.jpg